We are getting Closer #OncoAlert5k 🏃‍♂️‍➡️ at #ASCO26
Are you Ready?? Join US!!! May 30th, 2026 7am
SIGN UP HERE 👉 oncoalert.m-pages.com/LkNqua/the-o...

THE #ASCO26 Abstract Titles Are Out!!!

Browse Here👉www.asco.org/annual-meeting/search

NEWS FROM INDUSTRY: LITESPARK-012 Update in Kidney Cancer
Source: News Release MERCK

www.merck.com/news/merck-a...

Update on the Phase 3 LITESPARK-012 results in advanced renal cell carcinoma. Triplet therapy with pembrolizumab , lenvatinib , and belzutifan. The trial failed🚫 to improve PFS & OS

NEWS FROM INDUSTRY: KEYNOTE-B15 Update in Bladder Cancer
Source: Press Release MERCK
www.merck.com/news/fda-gra...

FDA🇺🇸 granted priority review to supplemental applications for pembrolizumab and pembrolizumab+ berahyaluronidase alfa-pmph, each combined with enfortumab Vedotin-ejfv),

A reminder that #APCCC26 🇨🇭is coming in Late April and is OPEN TO EVERYONE, not just the Panel members and 👉️ REGISTER HERE: buff.ly/XpCWPdR

🚨 Enjoy 20% off when registering for both APCCC & IPCS 2026

Awarm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭

Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study

www.thelancet.com/journals/lan...

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study

www.gynecologiconcology-online.net/article/S009...

Join APCCC26 in Lugano, 2026! 
FREE ONLINE REGISTRATION for participants from Low income or Lower Middle income!! REGISTER HERE 👉 buff.ly/qYCDm7I

The conference is open to everyone, offering two days of expert presentations, debates, and discussions on the latest in advanced #ProstateCancer care.

Join APCCC26 in Lugano, 2026! 

FREE ONLINE REGISTRATION for participants from Low income or Lower Middle income!!
REGISTER HERE 👉 apccc.org/apccc-2026/r...

An AMAZING #IKCSEU26 in Paris 🇫🇷 France
Thanking our partners at Kindey Cancer Association, our ambassadors, our colleagues worldwide who were reporting live on the great discussions and all those colleagues at home following along. A warm welcome to Join #IKCS26 in Dallas Texas this coming November

DAY THREE of OncoAlert 🚨 Coverage of #IKCSEU26
The Meet-URO Score Presenter Dr. Sara Rebuzzi 🇮🇹

The Meet-URO score is a novel prognostic tool for metastatic renal cell carcinoma, integrating the IMDC score with neutrophil-to-lymphocyte ratio and presence of bone metastases.

DAY THREE of OncoAlert 🚨 Coverage of #IKCSEU26
Triplet Therapy in First Line ccRCC Presenter Dr. Yüksel Ürün 🇹🇷

KEYMAKER-U03A: in kidney cancer, more is not more. Mechanism matters.
There is a signal. It will not change practice yet.
Waiting for LITESPARK-012.

DAY THREE of OncoAlert 🚨 Coverage of #IKCSEU26
CkOSMIC - One stop renal tumor diagnostic clinic Presenter Dr.Chiara Re 🇮🇹

CkOSMIC rethinks kidney cancer care. The first one-stop renal mass biopsy clinic delivering: - Same-day diagnosis & treatment plan - 94% sensitivity / 100%

Dear Colleagues,
OncoAlert Would like to Congratulate Kidney Cancer Association and all the faculty and staff who are making #IKCSEU26 🇫🇷 Possible.

Amazing Stats, Not even the close of the meeting and it has already OVER 4x the #IKCSEU26 and we are just getting Started
6️⃣ .6️⃣million Impressions

DAY THREE of OncoAlert 🚨 Coverage of #IKCSEU26
M1 - Defining subtype-specific PD-1, PD-L1 and CTLA-4 immunopositivity thresholds for personalized prognostication in surgically treated non-metastatic renal cell carcinoma Presenter Dr. Selcuc Erdem 🇹🇷

DAY THREE of OncoAlert 🚨 Coverage of #IKCSEU26
Microbiome impacting therapy with inulin gel in combination with ipilimumab and nivolumab in advanced renal cell carcinoma: ICON trial Dr. Ulka Vaishampayan 🇺🇸

Our Warmest congratulations to our @OncoAlert 🚨 faculty Dr. John Haanen 🇳🇱 on being awarded the N. Vogelzang Humanitarian Award at #IKCSEU26 🇫🇷
Kudos John!!!

DAY THREE of OncoAlert 🚨 Coverage of #IKCSEU26
Characteristics and outcome of pediatric renal tumors Presenter Dr. Marry M van den Heuvel-Eibrink 🇳🇱

Children and adults, both can suffer from kidney cancer. Important cancer types as Wilms tumor and Renal Cell Carcinoma.

DAY THREE of OncoAlert 🚨 Coverage of #IKCSEU26
KCA Updates by Salvatore La Rosa🇺🇸

The future of kidney cancer isn’t just presented—it’s built together. IKCS continues to evolve into a platform for collaboration, where ideas are tested, partnerships are formed, and science moves closer to patients.

Dear Colleagues
An Amazing START to the final day of #IKCSEU26 !!

✅5.2 million impressions and Counting
www.medtracksocial.com/hashtag/

Thanks to our partners at @KidneyCancer for a magnificent meetings and to our colleagues from keeping us up to date in real time

We are all OncoAlert 🚨

DAY TWO of OncoAlert 🚨 Coverage of #IKCSEU26
The management of renal manifestations in vhl syndrome: insights from a single institution's three-decade experience Presenter Dr. Selcuc Erdem 🇹🇷

Day TWO of OncoAlert 🚨 Coverage of #IKCSEU26
L3 - The accuracy of KEYNOTE-564 study eligibility criteria on recurrence prediction in papillary renal cell carcinoma: A multi-institutional comparative analysis with prognostic scores Presenter Dr. Selcuc Erdem 🇹🇷

DAY Two of OncoAlert 🚨 Coverage of #IKCSEU26
Leading Across Time: Women's Empowerment Legacy and the future of Oncology (Women and Allies in RCC session) Presenter Dr. Athina Christopoulou 🇬🇷

Empowering women’s leadership strengthens innovation, improves patient outcomes, and is essential!

DAY TWO of OncoAlert 🚨 Coverage of #IKCSEU26
Farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) combined with cabozantinib (cabo) in clear cell renal cell carcinoma (ccRCC) patients after prior exposure to cabo: Preliminary phase 1 results from FIT-001 Presenter Dr. Yousef Zakharia 🇺🇸

DAY TWO of OncoAlert 🚨 Coverage of #IKCSEU26

Preoperative risk prediction tool for cancer-specific and other cause mortality after surgery for non-metastatic renal cell carcinoma Presenter Dr. Philip Hedegaard 🇩🇰

DAY TWO of OncoAlert 🚨 Coverage of #IKCSEU26
Impact of intratumoral tertiary lymphoid structures on response and toxicity to immune checkpoint inhibitors from the bionikk trial in metastatic ccRCC
Presenter Dr. Isaias Hernandez-Verdin 🇫🇷

Great Discussions Happening at #IKCSEU26 in Beautiful Paris🇫🇷
Unfolding insights to RCC #KidneyCancer

DAY TWO of OncoAlert 🚨 Coverage of #IKCSEU26
Trial Resilience: Learning from Negative Outcomes Presenter Dr. Antonio Rullan 🇬🇧

Clinical trials with negative results are unfortunately too frequent. In this talk we discussed learning points from IMMOTION 151, CHECKMATE 914 and PROSPER

Join OncoAlert and our collaborators at Mirrors of Medicine for the 2026 Global Forum in GU Oncology—an excellent opportunity to learn how to translate the latest advances in oncology into your clinical practice.
👉 mirrorsmed.org/keep-me-info...
December 2–5, 2026
Amsterdam, Netherlands

DAY TWO of OncoAlert 🚨 Coverage of #IKCSEU26
Quality of Life and Survivorship with Adjuvant Immunotherapy: Insights From the Patient Experience Presenter Dr. Sophie Merrick 🇬🇧

Adjuvant ICIs are now standard of care in resected RCC, so understanding their impact on quality of life is essential.